Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05377554 · ClinicalTrials.gov registry record · Phase 3
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
A Phase 3 study, sponsored by Alume Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
NCT05377554 is a Phase 3 study that has completed, run by Alume Biosciences. The registered enrollment target is 154 participants.
The verdict
NCT05377554, a Phase 3 study, has completed, sponsored by Alume Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
Study Summary
This protocol describes prospective, open-label, blinded, randomized controlled, multicenter pivotal studies to evaluate bevonescein.
Interventions
- DRUG Bevonescein
- OTHER Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay
- OTHER Intra-operative Visualization using White Light Reflectance (WLR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2022-04-29 |
| Est. Completion | 2025-11-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05377554
The ClinicalTrials.gov registry entry for NCT05377554 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alume Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevonescein is the first listed.
NCT05377554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05377554 about?
NCT05377554 is a clinical study titled "Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery". This protocol describes prospective, open-label, blinded, randomized controlled, multicenter pivotal studies to evaluate bevonescein.
What is the current status of trial NCT05377554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2022-04-29. Estimated completion is 2025-11-24.
What interventions are being tested in trial NCT05377554?
The interventions under investigation include: Bevonescein (DRUG), Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay (OTHER), Intra-operative Visualization using White Light Reflectance (WLR) (OTHER).
Who is sponsoring clinical trial NCT05377554?
This trial is sponsored by Alume Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.